<HTML>
<HEAD>
<TITLE>Filed by Bowne Pure Compliance</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">
<DIV style="font-size: 10pt">
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 2pt solid">&nbsp;</DIV>
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 1pt solid">&nbsp;</DIV>

<P style="font-size: 14pt" align="center"><B>UNITED STATES<BR>
SECURITIES AND
EXCHANGE COMMISSION<BR>
<FONT style="font-size: 12pt">Washington, D.C. 20549
</FONT></B>

<P style="font-size: 18pt" align="center"><B>FORM 8-K</B>

<P style="font-size: 12pt" align="center"><B>CURRENT REPORT<BR>
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934</B>

<P style="font-size: 10pt" align="center"><B>Date of Report (Date of earliest
event reported): February 9, 2009</B>



<P style="font-size: 24pt" align="center"><B>HEARTWARE INTERNATIONAL,
INC.<BR>
</B><FONT style="font-size: 10pt">(Exact name of registrant as
specified in its charter) </FONT>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="32%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="33%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="32%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>Delaware</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>000-52595</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>26-3636023</B></TD>
 </TR>
 <TR valign="top">
  <TD>(State or other Jurisdiction of Incorporation)</TD>
  <TD>&nbsp;</TD>
  <TD>(Commission File Number)</TD>
  <TD>&nbsp;</TD>
  <TD>(IRS Employer Identification No.)</TD>
 </TR>

</TABLE>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="49%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="49%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>205 Newbury Street, Suite
101<BR>
Framingham, MA<BR>
</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>01701</B></TD>
 </TR>
 <TR valign="top">
  <TD>(Address of Principal Executive Offices)</TD>
  <TD>&nbsp;</TD>
  <TD>(Zip Code)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="center">Registrant&#8217;s telephone number,
including area code: <B>508.739.0950</B>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="30%" border="0">

 <TR>
  <TD width="100%">&nbsp;</TD>
 </TR>
 <TR>
  <TD style="border-bottom: #000000 1px solid" nowrap><B>&nbsp;</B></TD>
 </TR>
 <TR>
  <TD nowrap>(Former name or former address if changed since last report.)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="left">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:

<P style="font-size: 10pt" align="left"><FONT face="Wingdings">o</FONT> Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)<BR>
<BR>
<FONT face="Wingdings">o</FONT> Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>



<DIV
style="margin-top: 10pt; font-size: 1pt; width: 100%; border-bottom: black 1pt solid">&nbsp;</DIV>
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 2pt solid">&nbsp;</DIV>
</DIV>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">

<P style="font-size: 10pt" align="left"><B>Item&nbsp;7.01 Regulation&nbsp;FD
Disclosure</B>

<P style="font-size: 10pt" align="left">HeartWare International, Inc. (ASX:HIN)
announced today (February&nbsp;10, 2009 Australian Eastern Standard Time), via
an Australian Securities Exchange (&#8220;ASX&#8221;) announcement, that
Northwestern Memorial Hospital has become the third center to implant the
HeartWare<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>
Ventricular Assist System in the Company&#8217;s U.S. clinical trial. In its
first week, Northwestern conducted two HeartWare implants, on February&nbsp;2,
and February&nbsp;5, 2008, respectively.

<P style="font-size: 10pt" align="left">The implants were performed by Edwin C.
McGee, MD., surgical director of the Advanced Heart Failure Program of the
Bluhm Cardiovascular Institute at Northwestern. Dr.&nbsp;McGee is a renowned
cardiothoracic surgeon with special interest in heart failure, transplantation,
mechanical assistance, coronary surgery, valve repair and aortic surgery. He is
a member of the Northwestern Medical Faculty Foundation and an assistant
professor at the Feinberg School of Medicine.

<P style="font-size: 10pt" align="left">A total of 10 patients have been
enrolled to date in HeartWare&#8217;s pivotal Bridge-to-Transplant trial. The
trial will enroll up to 150 patients at a maximum of 28 centers.

<P style="font-size: 10pt" align="left">A copy of the complete ASX announcement
is attached.

<P style="font-size: 10pt" align="left"><B>Item&nbsp;9.01 Financial Statements
and Exhibits</B>

<P style="font-size: 10pt" align="left">Exhibit&nbsp;99.1 HeartWare
International, Inc. ASX announcement, dated February&nbsp;10, 2009

<P style="font-size: 10pt" align="left"><B>SIGNATURES</B>

<P style="font-size: 10pt" align="left">Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly authorized.

<P style="font-size: 10pt; margin-left: 46%" align="left">HeartWare
International, Inc.

<P style="font-size: 10pt" align="left">Date: February&nbsp;9, 2009

<P style="margin-top: -11pt; font-size: 10pt; margin-left: 46%"
align="left">By: <U>/s/ David McIntyre&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><br>Name: David McIntyre<BR>
Title: Chief Financial Officer and<BR>
Chief
Operating Officer

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">2
</DIV>
</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "c80695e8vk.htm", "description": "8-K", "secsgml_size_bytes": 6718}]
{"company-data": {"conformed-name": "HeartWare International, Inc.", "cik": "0001389072", "assigned-sic": "3841", "irs-number": "980498958", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-52595", "film-number": "09582216"}, "business-address": {"street1": "14000 NW 57TH COURT", "city": "MIAMI LAKES", "state": "FL", "zip": "33014", "phone": "508-739-0841"}, "mail-address": {"street1": "205 NEWBURY STREET", "street2": "SUITE 101", "city": "FRAMINGHAM", "state": "MA", "zip": "01701"}, "former-company": {"former-conformed-name": "HeartWare LTD", "date-changed": "20070206"}}
Filed by Bowne Pure Compliance
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest
event reported): February 9, 2009
HEARTWARE INTERNATIONAL,
INC.
(Exact name of registrant as
specified in its charter)
Delaware
000-52595
26-3636023
(State or other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
205 Newbury Street, Suite
101
Framingham, MA
01701
(Address of Principal Executive Offices)
(Zip Code)
Registrant's telephone number,
including area code:
508.739.0950
(Former name or former address if changed since last report.)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
o
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01 Regulation FD
Disclosure
HeartWare International, Inc. (ASX:HIN)
announced today (February 10, 2009 Australian Eastern Standard Time), via
an Australian Securities Exchange ("ASX") announcement, that
Northwestern Memorial Hospital has become the third center to implant the
HeartWare
®
Ventricular Assist System in the Company's U.S. clinical trial. In its
first week, Northwestern conducted two HeartWare implants, on February 2,
and February 5, 2008, respectively.
The implants were performed by Edwin C.
McGee, MD., surgical director of the Advanced Heart Failure Program of the
Bluhm Cardiovascular Institute at Northwestern. Dr. McGee is a renowned
cardiothoracic surgeon with special interest in heart failure, transplantation,
mechanical assistance, coronary surgery, valve repair and aortic surgery. He is
a member of the Northwestern Medical Faculty Foundation and an assistant
professor at the Feinberg School of Medicine.
A total of 10 patients have been
enrolled to date in HeartWare's pivotal Bridge-to-Transplant trial. The
trial will enroll up to 150 patients at a maximum of 28 centers.
A copy of the complete ASX announcement
is attached.
Item 9.01 Financial Statements
and Exhibits
Exhibit 99.1 HeartWare
International, Inc. ASX announcement, dated February 10, 2009
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly authorized.
HeartWare
International, Inc.
Date: February 9, 2009
By:
/s/ David McIntyre
Name: David McIntyre
Title: Chief Financial Officer and
Chief
Operating Officer